Drug Profile
THR 184
Alternative Names: AA-184; THR-184Latest Information Update: 12 Jun 2017
Price :
$50
*
At a glance
- Originator Thrasos Therapeutics
- Class Anti-inflammatories; Antifibrotics; Apoptosis regulatory proteins; Oligopeptides; Peptides; Small molecules
- Mechanism of Action Bone morphogenetic protein receptor type I agonists; Bone morphogenetic protein receptor type II agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute kidney injury
Most Recent Events
- 12 Jun 2017 Discontinued - Phase-II for Acute kidney injury (Prevention) in USA and Canada (IV)
- 29 Feb 2016 Efficacy and adverse events data from a phase II trial in Acute kidney injury released by Thrasos
- 29 Feb 2016 Thrasos completes a phase II trial in Acute kidney injury (Prevention) in USA and Canada